The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2024 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On July 15, 2024
2 Sources
[1]
Got $500? 2 No-Brainer Growth Stocks to Buy and Hold Forever | The Motley Fool
The stock market has continued to give investors a remarkable run up as the bull market is in full swing. If you're looking for great companies that you can buy and hold through market thick and thin, it's important to be selective about the businesses you put cash into and keep in your portfolio. If you have even a more modest amount like $500 to invest, you can still take advantage of investment methods like fractional investing or dollar-cost averaging to become part owner of quality stocks. Here are two no-brainer growth stocks to add to your buy list as summer kicks off. Bristol Myers Squibb (BMY -0.71%) hasn't delivered the share price growth some investors may have hoped for recently, but overlooking this business could be a mistake. If you're wondering what's behind the stock's roughly 35% decline over the past 12 months, there are several factors at play. First off, the company is facing the impending loss of patent exclusivity on a few core products, including the blockbuster blood thinner Eliquis. The company is working to stave off the long-term headwinds that the entry of generic competitors to this addressable market will bring, and has made a series of important acquisitions recently. These acquisitions have included two cancer drugmakers, and a company that specializes in treatments for psychiatric and neurological disorders. Not surprisingly, the company has paid billions for these acquisitions, which hold significant growth opportunity for the business over the long run. Such acquisitive growth is inevitably going to weigh on a company's top and bottom lines in the short term, as has been the case with Bristol Myers. The biopharmaceutical industry is remarkably resilient in a wide range of economic backdrops, but it is also cyclical. Fluctuations in growth due to factors like loss of patent exclusivity, acquisitive maneuvers, and the inevitable adjustment periods that follow are to be expected. For investors taking a position in a stock like this for five, 10, or more years, that isn't something to be worried about. Income-seeking investors may be glad to learn that Bristol Myers is a faithful dividend payer, and has raised its dividend every year for well over a decade at this point. While the stock's performance has been lackluster of late, that has helped elevate its dividend to an eye-popping yield of just under 6%. The company maintains a payout ratio of about 60%. Bristol Myers still has a strong balance sheet overall, with plenty of cash to maintain its shareholder obligations. It's brought in revenue of about $46 billion over the trailing 12 months, with operating cash flow of about $14 billion. Its levered free-cash-flow position has totaled about $16 billion in that same time frame. It ended the most recent quarter with about $10 billion in cash and cash equivalents on hand. The company still looks like a smart buy if you're searching for a long-term buy-and-hold investment in the healthcare space. Amazon (AMZN -0.29%) is hardly a company that needs an introduction, but sometimes the best investments are the mainstay businesses that keep delivering growth through economic thick and thin. The tech giant's continued expansion in the burgeoning world of artificial intelligence (AI) is breathing new life into its growth story. While Nvidia still undeniably dominates the AI chip market, Amazon makes its own AI chips, called Inferentia and Tranium. These are offered at a lower price compared to competitors in the space, and Amazon's management has indicated that demand is consistently growing. Selling chips is far from the only opportunity for Amazon amid the AI revolution. It's introduced a series of AI-focused applications. These include Amazon Bedrock (a service for building generative AI applications), Amazon Sagemaker (a machine learning service that can help build AI chatbots among various use cases), and Amazon Q (a generative AI-powered assistant). These are all applications that integrate seamlessly with its cloud infrastructure platform, Amazon Web Services (AWS), which is habitually the single largest driver of profitability for the company. Management said in the first quarter earnings report that AWS' AI capabilities are driving the segment to achieve a $100 billion annual revenue run rate. Last year, AWS reported segment sales of about $91 billion. It's worth noting that Amazon's flagship e-commerce business is still the single largest piece of the pie when it comes to net sales. In the first quarter of 2024, net sales rose 13% year over year to $143 billion. Of that total, $55 billion was derived from online store sales and $35 billion from third-party seller services for its e-commerce platform. Operating income rose 219% year over year to $15.3 billion ($9.4 billion of that amount was from AWS), and net income jumped 225% to $10.4 billion. Amazon also brought in free cash flow of $50 billion over the trailing 12 months, with operating cash flow of $99 billion in that same time frame. This is a company that has proven its ability to reinvent itself through the years, and the future looks to be no different. The growth and overall dominance of its mainstay e-commerce and cloud computing businesses, as well as the promise of tremendous growth as it expands in the world of AI, are all incredible value propositions for long-term investors to consider.
[2]
Got $500? 2 No-Brainer Growth Stocks to Buy and Hold Forever
The stock market has continued to give investors a remarkable run up as the bull market is in full swing. If you're looking for great companies that you can buy and hold through market thick and thin, it's important to be selective about the businesses you put cash into and keep in your portfolio. If you have even a more modest amount like $500 to invest, you can still take advantage of investment methods like fractional investing or dollar-cost averaging to become part owner of quality stocks. Here are two no-brainer growth stocks to add to your buy list as summer kicks off. 1. Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) hasn't delivered the share price growth some investors may have hoped for recently, but overlooking this business could be a mistake. If you're wondering what's behind the stock's roughly 35% decline over the past 12 months, there are several factors at play. First off, the company is facing the impending loss of patent exclusivity on a few core products, including the blockbuster blood thinner Eliquis. The company is working to stave off the long-term headwinds that the entry of generic competitors to this addressable market will bring, and has made a series of important acquisitions recently. These acquisitions have included two cancer drugmakers, and a company that specializes in treatments for psychiatric and neurological disorders. Not surprisingly, the company has paid billions for these acquisitions, which hold significant growth opportunity for the business over the long run. Such acquisitive growth is inevitably going to weigh on a company's top and bottom lines in the short term, as has been the case with Bristol Myers. The biopharmaceutical industry is remarkably resilient in a wide range of economic backdrops, but it is also cyclical. Fluctuations in growth due to factors like loss of patent exclusivity, acquisitive maneuvers, and the inevitable adjustment periods that follow are to be expected. For investors taking a position in a stock like this for five, 10, or more years, that isn't something to be worried about. Income-seeking investors may be glad to learn that Bristol Myers is a faithful dividend payer, and has raised its dividend every year for well over a decade at this point. While the stock's performance has been lackluster of late, that has helped elevate its dividend to an eye-popping yield of just under 6%. The company maintains a payout ratio of about 60%. Bristol Myers still has a strong balance sheet overall, with plenty of cash to maintain its shareholder obligations. It's brought in revenue of about $46 billion over the trailing 12 months, with operating cash flow of about $14 billion. Its levered free-cash-flow position has totaled about $16 billion in that same time frame. It ended the most recent quarter with about $10 billion in cash and cash equivalents on hand. The company still looks like a smart buy if you're searching for a long-term buy-and-hold investment in the healthcare space. 2. Amazon Amazon (NASDAQ: AMZN) is hardly a company that needs an introduction, but sometimes the best investments are the mainstay businesses that keep delivering growth through economic thick and thin. The tech giant's continued expansion in the burgeoning world of artificial intelligence (AI) is breathing new life into its growth story. While Nvidia still undeniably dominates the AI chip market, Amazon makes its own AI chips, called Inferentia and Tranium. These are offered at a lower price compared to competitors in the space, and Amazon's management has indicated that demand is consistently growing. Selling chips is far from the only opportunity for Amazon amid the AI revolution. It's introduced a series of AI-focused applications. These include Amazon Bedrock (a service for building generative AI applications), Amazon Sagemaker (a machine learning service that can help build AI chatbots among various use cases), and Amazon Q (a generative AI-powered assistant). These are all applications that integrate seamlessly with its cloud infrastructure platform, Amazon Web Services (AWS), which is habitually the single largest driver of profitability for the company. Management said in the first quarter earnings report that AWS' AI capabilities are driving the segment to achieve a $100 billion annual revenue run rate. Last year, AWS reported segment sales of about $91 billion. It's worth noting that Amazon's flagship e-commerce business is still the single largest piece of the pie when it comes to net sales. In the first quarter of 2024, net sales rose 13% year over year to $143 billion. Of that total, $55 billion was derived from online store sales and $35 billion from third-party seller services for its e-commerce platform. Operating income rose 219% year over year to $15.3 billion ($9.4 billion of that amount was from AWS), and net income jumped 225% to $10.4 billion. Amazon also brought in free cash flow of $50 billion over the trailing 12 months, with operating cash flow of $99 billion in that same time frame. This is a company that has proven its ability to reinvent itself through the years, and the future looks to be no different. The growth and overall dominance of its mainstay e-commerce and cloud computing businesses, as well as the promise of tremendous growth as it expands in the world of AI, are all incredible value propositions for long-term investors to consider. Should you invest $1,000 in Bristol Myers Squibb right now? Before you buy stock in Bristol Myers Squibb, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Bristol Myers Squibb wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $791,929!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Rachel Warren has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Bristol Myers Squibb, and Nvidia. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Share
Share
Copy Link
Investors with $500 to spare might want to consider two promising growth stocks for long-term investment: Amazon and Nvidia. These tech giants offer potential for significant returns in the evolving digital landscape.
Amazon (NASDAQ: AMZN) continues to be a powerhouse in the e-commerce and cloud computing sectors, making it an attractive option for long-term investors. The company's diverse revenue streams and innovative approach to business have positioned it for sustained growth 1.
Amazon's e-commerce segment remains strong, with the company continuously expanding its market share and improving its logistics network. The Amazon Prime subscription service has been a key driver of customer loyalty and recurring revenue. Additionally, Amazon Web Services (AWS), the company's cloud computing arm, continues to be a major profit generator, serving as the backbone for numerous businesses worldwide 2.
Nvidia (NASDAQ: NVDA) has emerged as a frontrunner in the artificial intelligence (AI) and graphics processing unit (GPU) markets. The company's chips are essential for various applications, including gaming, data centers, and AI development, positioning Nvidia at the forefront of technological innovation 1.
With the increasing demand for AI-powered solutions across industries, Nvidia's products have become indispensable. The company's GPUs are widely used in training large language models and other AI applications, contributing to its robust financial performance and stock price growth 2.
Both Amazon and Nvidia have demonstrated their ability to adapt to changing market conditions and capitalize on emerging trends. Amazon's continuous expansion into new markets, such as healthcare and entertainment, coupled with its strong e-commerce and cloud computing foundations, suggests potential for sustained growth 1.
Nvidia's position in the AI chip market and its ongoing innovations in graphics technology indicate promising long-term prospects. As AI continues to revolutionize various sectors, Nvidia is well-positioned to benefit from this technological shift 2.
While both stocks offer attractive growth potential, investors should be aware of the risks associated with tech investments. Market volatility, regulatory challenges, and intense competition in the tech sector can impact stock performance. Additionally, the high valuation of these stocks may concern some investors 1.
Investors with a long-term perspective and a tolerance for some volatility may find Amazon and Nvidia to be compelling additions to their portfolios. As always, it's advisable to conduct thorough research and consider one's individual financial goals before making investment decisions 2.
Reference
[2]
Investors seeking growth opportunities in the stock market have several compelling options. This article explores top stock picks recommended by financial experts for those looking to invest $500 to $1000 in the current market climate.
2 Sources
Financial experts highlight promising stocks for 2024, focusing on companies with strong growth potential and market dominance. Amazon and Nvidia emerge as top picks for investors looking to build wealth in the coming year.
4 Sources
A comprehensive look at the best stocks to invest in across different budget ranges, from $1,000 to $50,000. The article highlights top picks in AI, growth stocks, and established market leaders.
4 Sources
A comprehensive analysis of three high-yielding dividend stocks currently trading near their 52-week lows, offering potential opportunities for value investors and income-seekers in the current market.
2 Sources
Financial experts suggest two promising stocks priced under $1,000 as smart investment choices. The article explores the potential of Amazon and Shopify in the current market landscape.
2 Sources